Next Article in Journal
Isolation and Enhancement of a Homogenous in Vitro Human Hertwig’s Epithelial Root Sheath Cell Population
Next Article in Special Issue
Candidate Biomarkers for Genetic and Clinicopathological Diagnosis of Endometrial Cancer
Previous Article in Journal
Short-Term Chromium-Stress-Induced Alterations in the Maize Leaf Proteome
Previous Article in Special Issue
Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC
Int. J. Mol. Sci. 2013, 14(6), 11145-11156; doi:10.3390/ijms140611145
Article

Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients

1,* , 2
,
1
 and
3
1 Department of Nuclear Medicine, Zhejiang Provincial Corps Hospital, Chinese People's Armed Police Force, Jiaxing 314000, China 2 Department of Thoracic Surgery, Zhejiang Provincial Corps Hospital, Chinese People's Armed Police Force, Jiaxing 314000, China 3 Department of Laboratory Medicine, Zhejiang Provincial Corps Hospital, Chinese People's Armed Police Force, Jiaxing 314000, China
* Author to whom correspondence should be addressed.
Received: 20 February 2013 / Revised: 7 April 2013 / Accepted: 14 May 2013 / Published: 27 May 2013
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
View Full-Text   |   Download PDF [786 KB, uploaded 19 June 2014]   |   Browse Figures

Abstract

The aim of this study was to investigate the prognostic value of tumor markers in operable non-small cell lung cancer (NSCLC) patients. A total of 481 NSCLC patients were enrolled in the present study. High levels of neuron-specific enolase (NSE), carbohydrate antigen 125 (CA125) and squamous cell carcinoma antigen (SCC) were detected in 306 (63.6%), 89 (18.5%) and 125 (26.0%) patients, respectively. Seventy-eight of 481 patients died of disease progression, and the median disease-free survival (DFS) and overall survival (OS) were 16.0 and 21.0 months, respectively. The three-year DFS rate was 56.7%, and the OS rate was 75.3%. For serum NSE, the three-year cumulative DFS rate for the normal and elevated group was 67.7% and 51.8% (p = 0.007). The OS in patients with high and normal levels of NSE was 34.0 months and 48.0 months, respectively. The median DFS was 46.0 months versus 32.0 months (p = 0.001), and the OS was 48.0 months versus 44.0 months (p = 0.001) in patients with normal and high levels of CA125. For patients with squamous cell carcinoma, the overall survival was significantly shorter in patients with elevated levels of SCC (p = 0.041). In the multivariate analysis high levels of NSE, CA125 and clinical stage were significantly correlated with worse prognosis (p < 0.05). Patients with all three tumor markers elevated presented the worst prognosis (p < 0.05). In our analysis, high levels of preoperative serum NSE and CA125 are correlated with worse survival in operable NSCLC patients.
Keywords: tumor marker; CA125; NSE; SCC; lung cancer tumor marker; CA125; NSE; SCC; lung cancer
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Yu, D.; Du, K.; Liu, T.; Chen, G. Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients. Int. J. Mol. Sci. 2013, 14, 11145-11156.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert